8-K: Beyond Air CFO Resigns, Interim Successor Named

Beyond Air, Inc. announced the resignation of Chief Financial Officer Doug Larson, effective December 5, 2025, with Duke Drewell stepping in as interim CFO.

Summary

• Doug Larson resigned as Chief Financial Officer of Beyond Air, Inc. to pursue another opportunity.
• His resignation is effective December 5, 2025.
• Mr. Larson will serve in an advisory role through calendar year-end 2025 to ensure a smooth transition.
• Duke Drewell, the Company's Controller, will assume CFO responsibilities on an interim basis.
• Beyond Air has initiated a search for a permanent successor.
• The departure is not due to any disagreements regarding financial statements, internal control over financial reporting, operations, policies, or practices.

Sentiment

Score: 6

Explanation: The resignation of a CFO is generally a neutral to slightly negative event due to potential disruption. However, the explicit statement that it's not due to disagreements, the smooth transition plan, and the outgoing CFO's positive comments about the company's financial health (recent financing) mitigate the negative impact, leaning towards a neutral to slightly positive interpretation of the handling of the event.

Positives

• The departure is explicitly stated not to be the result of any disagreements with the Company on financial statements, internal control, operations, policies, or practices.
• Mr. Larson will remain in an advisory role through year-end 2025 to support a smooth transition.
• Management expressed gratitude for Mr. Larson's contributions, particularly in the transition to a commercial business with LungFit PH and the launch of subsidiaries.
• Mr. Larson expressed confidence in the company's future, especially following recent financing agreements that strengthened the balance sheet.

Negatives

• The departure of a key executive like the CFO can introduce uncertainty and potential disruption, even with a smooth transition plan.

Risks

• Ability to raise additional capital.
• Timing and results of future pre-clinical studies and clinical trials.
• Potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for product candidates.
• The approach to discover and develop novel drugs is unproven and may never lead to efficacious or marketable products.
• Ability to fund and the results of further pre-clinical studies and clinical trials of product candidates.
• Obtaining, maintaining, and protecting intellectual property utilized by products.
• Obtaining regulatory approval for products.
• Competition from others using similar technology and others developing products for similar uses.
• Dependence on collaborators.

Future Outlook

The company is actively searching for a permanent Chief Financial Officer. Management expressed confidence in the company's future positioning, particularly after recent financing agreements strengthened the balance sheet. The company continues to advance its LungFit systems in clinical trials and pursue pre-clinical programs for neurological disorders and solid tumors.

Management Comments

• "Doug has been a valued member of our team over the past four years. His leadership and financial discipline were instrumental in our transition to a commercial business with the launch of the LungFit PH, as well as the launch of our majority owned clinical research stage subsidiaries, Beyond Cancer and NeuroNOS. We are grateful for his contributions through these defining moments in our Companys history and wish him continued success in his future endeavors." Steve Lisi, Chairman and Chief Executive Officer.
• "I have enjoyed being part of the Beyond Air team over the past several years, as we have guided the business from development-stage to a fully commercial enterprise. I am proud of what we accomplished together and confident that the company is well-positioned for the future, particularly following the recent financing agreements that strengthened the balance sheet." Doug Larson.

Industry Context

The departure of a CFO is a common occurrence in the dynamic biopharmaceutical and medical device industry, often driven by individuals seeking new opportunities. Beyond Air's focus on nitric oxide therapies for various conditions places it in a specialized niche within the broader healthcare sector, where executive leadership is crucial for navigating regulatory landscapes, clinical development, and commercialization efforts.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Potential short-term uncertainty due to executive change, but mitigated by smooth transition plan and positive statements about company's financial health. Long-term impact depends on the quality of the permanent successor.
• Employees: Potential for minor disruption in the finance department, but the interim appointment and advisory role should ensure continuity.
• Customers/Suppliers: Unlikely to have a direct impact as the change is internal finance leadership.
• Creditors: The mention of "recent financing agreements that strengthened the balance sheet" suggests a positive outlook on the company's financial stability, which is favorable for creditors.

Next Steps

• Beyond Air will conduct a search for a permanent Chief Financial Officer.
• Duke Drewell will serve as interim CFO.
• Doug Larson will serve in an advisory role through calendar year-end 2025.
• The company continues to advance its LungFit systems in clinical trials.
• Beyond Cancer, Ltd. is conducting preclinical studies and a first-in-human study for solid tumors.
• NeuroNOS continues preclinical studies for neurodevelopmental and neurodegenerative disorders.

Key Dates

Recommendation

The resignation of the CFO, while a key executive change, is presented as a smooth transition with no underlying disagreements regarding financial practices. The company has an interim CFO in place and is actively searching for a permanent successor. The outgoing CFO's positive remarks about the company's strengthened balance sheet from recent financing are reassuring. For a seasoned investor, this event does not fundamentally alter the investment thesis for Beyond Air, warranting a 'hold' position to observe the appointment of a permanent CFO and continued operational execution.

Keywords

Beyond Air, XAIR, CFO resignation, Chief Financial Officer, executive change, medical device, biopharmaceutical, nitric oxide, LungFit PH, corporate governance